Demographics and tau CSF marker concentrations for healthy controls, groups split by Duits criteria for likely AD pathology (vs FTLD pathology) and groups split by likely FTLD-tau and FTLD-TDP-43 pathology
| Healthy control | Aβ42<550 µL | Aβ42>550 µL | Probable tau pathology | Probable TDP-43 pathology | |
| N | 20 | 21 | 45 | 7 | 18 |
| Male gender N (% group) | 10 (50.0) | 11 (52.3) | 34 (75.5) | 5 (71.4) | 13 (72.2) |
| Age at CSF (years) Mean (SD) | 64.2 (6.9) | 65.8 (6.1) | 64.1 (6.6) | 64.8 (8.8) | 62.3 (5.9) |
| T-tau pg/mL Mean (SD) | 326.6 (90.8) | 722.7 (529.1) | 464.7 (344.1) | 444.4 (146.4) | 457.1 (224.6) |
| P-tau(181) pg/mL Mean (SD) | 51.1 (11.9) | 72.1 (42.3) | 51.3 (24.1) | 53.5 (13.9) | 47.2 (16.5) |
| Tau N-123 pg/mL Mean (SD) | 85.8 (115.7) | 77.4 (77.4) | 74.0 (82.5) | 54.9 (53.5) | 70.6 (87.0) |
| Tau N-mid-region pg/mL Mean (SD) | 153.4 (63.8) | 294.7 (179.2) | 216.7 (132.6) | 215.4 (71.4) | 235.1 (123.3) |
| Tau N-224 pg/mL Mean (SD) | 6.0 (3.4) | 10.8 (8.2) | 9.3 (8.2) | 13.9 (13.1) | 8.5 (4.7) |
| Non-phosphorylated tau pg/mL Mean (SD) | 39.4 (17.6) | 77.2 (53.4) | 57.0 (35.7) | 51.4 (20.7) | 62.5 (32.9) |
| Tau X-368 pg/mL Mean (SD) | 16.0 (4.1) | 16.3 (6.3) | 15.2 (4.8) | 15.1 (2.9) | 15.6 (4.1) |
AD, Alzheimer's disease; CSF, cerebrospinal fluid; FTD, frontotemporal dementia; FTLD, frontotemporal lobar degeneration.